124 related articles for article (PubMed ID: 12943199)
1. Retinoic acid metabolism inhibition by 3-azolylmethyl-1H-indoles and 2, 3 or 5-(alpha-azolylbenzyl)-1H-indoles.
Le Borgne M; Marchand P; Le Baut G; Ahmadi M; Smith HJ; Nicholls PJ
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):155-8. PubMed ID: 12943199
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)-1H-indoles as selective aromatase inhibitors.
Le Borgne M; Marchand P; Nourrisson MR; Loquet D; Palzer M; Le Baut G; Hartmann RW
J Enzyme Inhib Med Chem; 2007 Oct; 22(5):667-76. PubMed ID: 18035835
[TBL] [Abstract][Full Text] [Related]
3. Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.
Marchand P; Le Borgne M; Palzer M; Le Baut G; Hartmann RW
Bioorg Med Chem Lett; 2003 May; 13(9):1553-5. PubMed ID: 12699753
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom.
Le Borgne M; Marchand P; Duflos M; Delevoye-Seiller B; Piessard-Robert S; Le Baut G; Hartmann RW; Palzer M
Arch Pharm (Weinheim); 1997 May; 330(5):141-5. PubMed ID: 9237426
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antileishmanial activity of 3-(alpha-azolylbenzyl)indoles.
Marchand P; Le Borgne M; Na YM; Pagniez F; Abdala H; Le Baut G; Le Pape P
J Enzyme Inhib Med Chem; 2002 Dec; 17(6):353-8. PubMed ID: 12683669
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles.
Pautus S; Yee SW; Jayne M; Coogan MP; Simons C
Bioorg Med Chem; 2006 Jun; 14(11):3643-53. PubMed ID: 16458519
[TBL] [Abstract][Full Text] [Related]
8. New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles.
Le Borgne M; Marchand P; Delevoye-Seiller B; Robert JM; Le Baut G; Hartmann RW; Palzer M
Bioorg Med Chem Lett; 1999 Feb; 9(3):333-6. PubMed ID: 10091679
[TBL] [Abstract][Full Text] [Related]
9. Some 1,2-diphenylethane derivatives as inhibitors of retinoic acid--metabolising enzymes.
Greer VP; Mason P; Kirby AJ; Smith HJ; Nicholls PJ; Simons C
J Enzyme Inhib Med Chem; 2003 Oct; 18(5):431-43. PubMed ID: 14692511
[TBL] [Abstract][Full Text] [Related]
10. Some aryl substituted 2-(4-nitrophenyl)-4-oxo-4-phenylbutanoates and 3-(4-nitrophenyl)-1-phenyl-1,4-butanediols and related compounds as inhibitors of rat liver microsomal retinoic acid metabolising enzymes.
Mason P; Greer VP; Kirby AJ; Simons C; Nicholls PJ; Smith HJ
J Enzyme Inhib Med Chem; 2003 Dec; 18(6):511-28. PubMed ID: 15008516
[TBL] [Abstract][Full Text] [Related]
11. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Sanwald P; David M; Dow J
Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
[TBL] [Abstract][Full Text] [Related]
13. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.
Gomaa MS; Armstrong JL; Bobillon B; Veal GJ; Brancale A; Redfern CP; Simons C
Bioorg Med Chem; 2008 Sep; 16(17):8301-13. PubMed ID: 18722776
[TBL] [Abstract][Full Text] [Related]
14. Some 3-(4-aminophenyl)pyrrolidine-2,5-diones as all-trans-retinoic acid metabolising enzyme inhibitors (RAMBAs).
Kirby AJ; Lelain R; Mason P; Maharlouie F; Nicholls PJ; Smith HJ; Simons C
J Enzyme Inhib Med Chem; 2002 Oct; 17(5):321-7. PubMed ID: 12683748
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
Li J; Nie C; Qiao Y; Hu J; Li Q; Wang Q; Pu X; Yan L; Qian H
Eur J Med Chem; 2019 Sep; 178():433-445. PubMed ID: 31202991
[TBL] [Abstract][Full Text] [Related]
17. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527
[TBL] [Abstract][Full Text] [Related]
18. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
19. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
20. Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat.
Swinney DC
Drug Metab Dispos; 1990; 18(6):859-65. PubMed ID: 1981529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
